168 related articles for article (PubMed ID: 10385364)
1. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Saji S; Sakamoto J; Teramukai S; Kunieda K; Sugiyama Y; Ohashi Y; Nakazato H
Surg Today; 1999; 29(6):504-10. PubMed ID: 10385364
[TBL] [Abstract][Full Text] [Related]
2. Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK.
Sakamoto J; Koike A; Saji S; Teramukai S; Ohashi Y; Nakazato H
Surg Today; 1992; 22(6):530-6. PubMed ID: 1472793
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Sakamoto J; Teramukai S; Koike A; Saji S; Ohashi Y; Nakazato H
Cancer; 1996 Jun; 77(11):2206-12. PubMed ID: 8635085
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers for immunochemotherapy using tegafur -uracil (UFT) and protein-bound polysaccharide K (PSK).
Yoshinaga K; Saeki H; Oki E; Morita M; Ikeda T; Sugimachi K; Yamashita Y; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Kawanaka H; Mimori K; Watanabe M; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):549-58. PubMed ID: 24693683
[TBL] [Abstract][Full Text] [Related]
5. [[Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group])].
Imaizumi M; Kondo T; Kamei H; Ichihashi H
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2397-403. PubMed ID: 2124433
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Hsu JT; Hsu CS; Le PH; Chen TC; Chou WC; Lin CY; Yeh TS
J Surg Res; 2017 May; 211():30-38. PubMed ID: 28501128
[TBL] [Abstract][Full Text] [Related]
7. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and PSK to carbazilquinone in patients with curative gastric resection.
Kondo T; Sakamoto J; Nakazato H
Biotherapy; 1991; 3(4):287-95. PubMed ID: 1786194
[TBL] [Abstract][Full Text] [Related]
8. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group].
Ichihashi H; Kondo T; Nakazato H
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2758-66. PubMed ID: 3307635
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer.
Okinaga K; Iinuma H; Kitamura Y; Yokohata T; Inaba T; Fukushima R
J Exp Clin Cancer Res; 2006 Sep; 25(3):339-49. PubMed ID: 17167974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Nakazato H; Koike A; Saji S; Ogawa N; Sakamoto J
Lancet; 1994 May; 343(8906):1122-6. PubMed ID: 7910230
[TBL] [Abstract][Full Text] [Related]
11. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: identification of responders incorporating the age factor.
Munemoto Y; Iida Y; Ohata K; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Oncol Rep; 2004 Mar; 11(3):623-35. PubMed ID: 14767513
[TBL] [Abstract][Full Text] [Related]
12. Clinical potential of biological response modifiers combined with chemotherapy for gastric cancer. Japanese experience.
Shibata M; Nezu T; Fujisaki S; Andou K; Tomita R; Fukuzawa M
Dig Surg; 2002; 19(4):255-60. PubMed ID: 12207066
[TBL] [Abstract][Full Text] [Related]
13. Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer.
Ogoshi K; Kondoh Y; Tajima T; Mitomi T
Cancer Immunol Immunother; 1992; 35(3):175-80. PubMed ID: 1638553
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.
Katoh R; Takenoshita S; Shimizu Y; Tanaka S; Yajima Y; Nagamachi Y
Anticancer Res; 1997; 17(5B):3787-92. PubMed ID: 9427781
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of immunochemotherapy for gastric cancer: a review of the current status.
Toge T
Semin Surg Oncol; 1999 Sep; 17(2):139-43. PubMed ID: 10449686
[TBL] [Abstract][Full Text] [Related]
16. Preservation of the spleen improves survival after radical surgery for gastric cancer.
Griffith JP; Sue-Ling HM; Martin I; Dixon MF; McMahon MJ; Axon AT; Johnston D
Gut; 1995 May; 36(5):684-90. PubMed ID: 7797117
[TBL] [Abstract][Full Text] [Related]
17. Gastric cancer in Asia: progress and controversies in surgical management.
Branicki FJ; Chu KM
Aust N Z J Surg; 1998 Mar; 68(3):172-9. PubMed ID: 9563443
[TBL] [Abstract][Full Text] [Related]
18. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer.
Tsujitani S; Kakeji Y; Orita H; Watanabe A; Kohnoe S; Baba H; Anai H; Maehara Y; Sugimachi K
Anticancer Res; 1992; 12(3):645-8. PubMed ID: 1622120
[TBL] [Abstract][Full Text] [Related]
19. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: Association between host or tumor factors and survival.
Munemoto Y; Iida Y; Abe J; Saito H; Fujisawa K; Kasahara Y; Mitsui T; Asada Y; Miura S
Int J Oncol; 2002 Feb; 20(2):403-11. PubMed ID: 11788909
[TBL] [Abstract][Full Text] [Related]
20. An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter.
Sugita M; Izuno T; Kanamori M; Ogoshi K; Mitomi T
Cancer Immunol Immunother; 1995 Oct; 41(4):251-6. PubMed ID: 7489568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
